<DOC>
	<DOC>NCT00848692</DOC>
	<brief_summary>Based on pilot patient observations,the investigators anticipate that chronic fatigue syndrome (CFS) patients may benefit from B-cell depletion therapy. The hypothesis is that at least a subset of CFS patients have an activated immune system involving B-lymphocytes, and that B-cell depletion may alleviate symptoms.</brief_summary>
	<brief_title>Drug Intervention in Chronic Fatigue Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome, Chronic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>verified chronic fatigue syndrome (CDCcriteria) age &gt;18 and &lt;60 years informed consent pregnancy or lactation previous malignant disease except basal cell carcinoma of skin and cervical carcinoma in situ previous longterm use of immunosuppressive drugs previous exposure to rituximab endogenous depression multiallergy with risk of serious drug reaction reduced renal function (creatinin &gt; 1.2 x UNL) reduced liver function (bilirubin or transaminases &gt; 1.5 x UNL) known HIV infection signs of active viral infection by pretreatment investigations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Chronic Fatigue Syndrome</keyword>
	<keyword>CFS</keyword>
	<keyword>Myalgic Encephalomyelitis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B-lymphocyte depletion</keyword>
	<keyword>B-cell depletion</keyword>
</DOC>